Hepatotropic Viral Infection Associated Systemic Vasculitides-Hepatitis B Virus Associated Polyarteritis Nodosa and Hepatitis C Virus Associated Cryoglobulinemic Vasculitis

Journal of Clinical and Experimental Hepatology

Volumn 3, Issue 3, 2013, Pages 204-212

  Sharma, Aman ^a   Sharma, Kusum ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Cryoglobulinemic vasculitis; HBV; HCV; Polyarteritis nodosa

Indexed keywords

ADEFOVIR; AMINOTRANSFERASE; BELIMUMAB; BOCEPREVIR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ENTECAVIR; EPRATUZUMAB; LAMIVUDINE; OCRELIZUMAB; OFATUMUMAB; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; RITUXIMAB; TELAPREVIR; TELBIVUDINE; TENOFOVIR; VIDARABINE; VIRUS DNA; VIRUS RNA;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTHRITIS; CARDIOMYOPATHY; CLINICAL FEATURE; CRYOGLOBULINEMIA; CRYOGLOBULINEMIC VASCULITIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; GASTROINTESTINAL DISEASE; GLOMERULONEPHRITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HYPERTENSION; IMMUNOTHERAPY; INCIDENCE; MESENTERIC ARTERY; MICROANEURYSM; MONONEUROPATHY MULTIPLEX; MORTALITY; ORCHITIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PURPURA; RAYNAUD PHENOMENON; RELAPSE; REVIEW; SJOEGREN SYNDROME; SKIN ULCER; VASCULITIS; WEIGHT REDUCTION;

EID: 84884589473     PISSN: 09736883     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jceh.2013.06.001     Document Type: Review

References (72)

1. Pleister A., Eckels D.D. Cryptic infection and autoimmunity. Autoimmun Rev 2003, 2:126-132.
2. Guillevin L. Virus-induced systemic vasculitides: new therapeutic approaches. Clin Dev Immunol 2004, 11:227-231.
3. Kussmaul A., Maier R. Ueber eine bisher nicht beschriebene eigenthümliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskell ähmung einhergeht. Dtsch Arch Klin Med 1866, 1:484-518.
4. Trepo C., Thivolet J. Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang 1970, 19:410-411.
5. Gocke D.J., Hsu K., Morgan C., Bombardieri S., Lockshin M., Christian C.L. Association between polyarteritis and Australia antigen. Lancet 1970, 2:1149-1153.
6. Pagnoux C., Cohen P. Guillevin L. Vasculitides secondary to infections. Clin Exp Rheumatol 2006, 24(suppl 41):S71-S81.
7. Cacoub P., Lunel-Fabiani F., Le Thi Huong D. Polyarteritis nodosa and hepatitis C virus infection. Ann Intern Med 1992, 116:605-606.
8. Servant A., Bogard M., Delaugerre C., Cohen P., Deny P., Guillevin L. GB virus C in systemic medium- and small-vessel necrotizing vasculitides. Br J Rheumatol 1998, 37:1292-1294.
9. Scott D.G., Bacon P.A., Elliott P.J., Tribe C.R., Wallington T.B. Systemic vasculitis in a district general hospital 1972-1980: clinical and laboratory features, classification and prognosis of 80 cases. QJM 1982, 51:292-311.
10. McMahon B.J., Heyward W.L., Templin D.W., Clement D., Lanier A.P. Hepatitis B-associated polyarteritis nodosa in Alaskan Eskimos: clinical and epidemiologic features and long-term follow-up. Hepatology 1989, 9:97-101.
11. Guillevin L., Mahr A., Callard P., et al. Hepatitis B virus-associated polyarteritis nodosa. Clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine 2005, 84:313-322.
12. Lane S.E., Watts R., Scott D.G. Epidemiology of systemic vasculitis. Curr Rheumatol Rep 2005, 7:270-275.
13. Guillevin L., Lhote F., Cohen P., et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995, 74:238-253.
14. Belizna C.C., Hamidou M.A., Levesque H., Guillevin L., Shoenfeld Y. Infection and vasculitis. Rheumatology (Oxford) 2009, 48:475-482.
15. Mahr A., Guillevin L., Poissonnet M., Ayme S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: acapture-recapture estimate. Arthritis Rheum 2004, 51:92-99.
16. Pernice W., Sodomann C.P., Luben G., Seiler F.R., Sedlacek H.H. Antigenspecific detection of HBsAG-containing immune complexes in the course of hepatitis B virus infection. Clin Exp Immunol 1979, 37:376-380.
17. Trepo C., Zuckerman A., Bird R., Prince A. The role of circulating hepatitis B antigen/antibody immune complexes in the pathogenesis of vascular and hepatic manifestations in polyarteritis nodosa. JClin Pathol 1974, 27:863-868.
18. Zuckerman A.J. Proceedings: hepatitis B, immune complexes, and thepathogenesis of polyarteritis nodosa. JClin Pathol 1976, 29:84-85.
19. Michalak T. Immune complexes of hepatitis B surface antigen in the pathogenesis of periarteritis nodosa. Am J Pathol 1978, 90:619-632.
20. Castaigne P., Cambier J., Escourolle R., et al. Les manifestations nerveuses de la pe'riarte'rite noueuse. A propos d'une observation antomo-clinique. Ann de Me'decine Interne (Paris) 1970, 121:375-376.
21. Naniwa T., Maeda T., Shimizu S., Ito R. Hepatitis B virus-related polyarteritis nodosa presenting with multiple lung nodules and cavitary lesions. Chest 2010, 138:195-197.
22. Pagnoux C., Seror R., Henegar C., et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa. A retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. Arthritis Rheum 2010, 62:616-626.
23. Lightfoot R.W., Michel B.A., Bloch D.A., et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990, 33:1088-1093.
24. Jennette J.C., Falk R.J., Andrassy K., et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994, 37:187-192.
25. Jennette J.C., Falk R.J., Bacon P.A., et al. 2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013, 65:1-11.
26. Hegener C., Pagnoux C., Puechal X., et al. Aparadigm of diagnostic criteria for polyarteritis nodosa. Analysis of a series of 949 patients with vasculitis. Arthritis Rheum 2008, 58:1528-1538.
27. Servoss J.C., Friedman L.S. Serologic and molecular diagnosis of hepatitis B virus. Infect Dis Clin North Am 2006, 20:47-61.
28. Watts R., Lane S., Hanslik T., et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007, 66:222-227.
29. Hagen E.C., Daha M.R., Hermans J., et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int 1998, 53:743-753. for the EC/BCR Project for ANCA Assay Standardization.
30. Gayraud M., Guillevin L., le Toumelin P., et al. Long-term follow up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001, 44:666-675.
31. Guillevin L., Lhote F., Gayraud M., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996, 75:17-28.
32. Mukhtyar C., Lee R., Brown D., et al. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis 2009, 68:1827-1832.
33. Trépo C., Ouzan D., Delmont J., Tremis J. Supérioritéd'un nouveau traitement étiopathogénique guérissant la périartérte noueuse due au virus de l'hépatite B par la combinaison d'une brève corticothérapie, de vidarabine et d'échanges plasmatiques". Presse Med 1988, 17:1527-1531.
34. Guillevin L., Merrouche Y., Gayraud M., et al. Périartérite noueuse due au virus de l'hépatite B. Détermination d'une nouvelle stratégie thérapeutique chez 13 patients. Presse Med 1988, 17:1522-1526.
35. Guillevin L., Lhote F., Leon A., Fauvelle F., Vivitski L., Trepo C. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. JRheumatol 1993, 20:289-298.
36. Guillevin L., Lhote F., Sauvaget F., et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994, 53:334-337.
37. Guillevin L., Mahr A., Cohen P., et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 2004, 51:482-487.
38. Meltzer M., Franklin E.C. Cryoglobulinemia-a study of twenty nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am J Med 1966, 40:828-836.
39. Brouet J.C., Clauvel J.P., Danon F., Klein M., Seligmann M. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med 1974, 57:775-788.
40. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a c DNA clone derived from a blood borne non-A, non-B viral genome. Science 1989, 244:359-362.
41. Sansonno D., Devita S., Cornacchiulo V., Carbone A., Baiocchi M., Dammacco F. Detection and distribution of hepatitis C related proteins in lymph nodes of patients with type II cryoglobulinemia and neoplastic or non-neoplastic lymphoproliferation. Blood 1996, 88:4638-4645.
42. Ferri C., Zignego A.L., Pileri S.A. Cryoglobulins. JClin Pathol 2002, 55:4-13.
43. Ferri C., Pileri S.A., Zignego A.L. Hepatitis C virus, B-cell disorders, and non-Hodgkin's lymphoma. Infectious Causes of Cancer. Targets for Intervention 2000, vol.19:349-368. Totowa (NJ) National Cancer Institute (NIH), The Humana Press Inc. J.J. Goedert (Ed.).
44. Invernizzi F., Pietrogrande M., Sagramoso B. Classification of cryoglobulinemic syndromes. Clin Exp Rheumatol 1995, 13(suppl 13):S123-S128.
45. Rieu V., Cohen P., André M.H., et al. Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. Rheumatology (Oxford) 2002, 41:290-300.
46. Authier F.J., Pawlotsky J.M., Viard J.P., Guillevin L., Degos J.D., Gherardi R.K. High incidence of hepatitis C virus infection in patients with cryoglobulinemic neuropathy. Ann Neurol 1993, 34:749-750.
47. Ferri C., Sebastiani M., Giuggioli D., et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004, 33:355-374.
48. Ferri C., Civita L., Cirafisi C., et al. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiological investigations. JRheumatol 1992, 19:889-895.
49. Gemignani F., Melli G., Inglese C., Marbini A. Cryoglobulinemiais a frequent cause of peripheral neuropathy in undiagnosed referral patients. JPeripher Nerv Syst 2002, 7:59-64.
50. Origgi L., Vanoli M., Carbone A., Grasso M., Scorza R. Central nervous system involvement in patients with HCV-related cryoglobulinemia. Am J Med Sci 1998, 315:208-210.
51. Sansonno D., Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 2005, 5:227-236.
52. Beddhu S., Bastacky S., Johnson J.P. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 2002, 81:398-409.
53. Sansonno D., Lauletta G., Nisi L., et al. Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia. Clin Exp Immunol 2003, 133:275.
54. Roccatello D., Fornasieri A., Giachino O., et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007, 49:69-82.
55. Tarantino A., Campise M., Banfi G., et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995, 47:618-623.
56. Terrier B., Saadoun D., Sene D., Scerra S., Musset L., Cacoub P. Presentation and outcome of gastrointestinal involvement in hepatitis C virus-related systemic vasculitis: a case-control study from a single-centre cohort of 163 patients. Gut 2010, 59:1709-1715.
57. Ramos-Casals M., Robles A., Brito-Zerón P., et al. Lifethreatening cryoglobulinaemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum 2006, 36:189-196.
58. Vita S.D., Soldano F., Isola M., et al. Preliminary classification criteria for the cryoglobulinemic vasculitis. Ann Rheum Dis 2012, 70:1183-1190.
59. Cacoub P., Saadoun D., Limal N., Sene D., Lidove O., Piette J.C. PEGylated interferon Alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005, 52:911-915.
60. Batisse D., Karmochkine M., Jacquot C., Kazatchkine M.D., Weiss L. Sustained exacerbation of cryoglobulinaemia related vasculitis following treatment of hepatitis C with peginterferon alfa. Eur J Gastroenterol Hepatol 2004, 16:701-703.
61. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444.
62. Rasul I., Shepherd F.A., Kamel-Reid S., Krajden M., Pantalony D., Jenny Heathcote E. Detection of occult low-grade B-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Hepatology 1999, 29:543-547.
63. Landau D.A., Scerra S., Sene D., Resche-Rigon M., Saadoun D., Cacoub P. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy. JRheumatol 2010, 37:615-621.
64. Sansonno D., De Re V., Lauletta G., Tucci F.A., Boiocchi M., Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood 2003, 101:3818-3826.
65. Zaja F., De Vita S., Mazzaro C., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003, 101:3827-3834.
66. Quartuccio L., Soardo G., Romano G., et al. Rituximab treatment for glomerulonep hritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology 2006, 45:842-846.
67. Ferri C., Cacoub P., Mazzaro C., et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011, 11:48-55.
68. De Vita S., Quartuccio L., Masolini P., et al. Arandomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (RTX) monotherapy versus the best available treatment (BAT) in patients with mixed cryoglobulinemia syndrome (MC). Ann Rheum Dis 2010, 69(suppl 3):93.
69. Pietrogrande M., De Vita S., Zignego A.L., et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011, 10:444-454.
70. De Vita S., Quartuccio L., Isola M., et al. Arandomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012, 64:843-853.
71. Sneller M.C., Hu Z., Langford C.A. Arandomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012, 64:835-842.
72. Saadoun D., Rosenzwajg M., Joly F., et al. Regulatory T cell responses to low-dose interleukin-2 in HCV-induced vasculitis. NEngl J Med 2011, 365:2067-2077.